步长制药：第五届董事会第二十八次会议决议公告

Core Viewpoint - The company announced the approval of several significant resolutions during its board meeting, indicating strategic moves in its operations and partnerships [1] Group 1: Company Announcements - The company approved a resolution regarding the signing of an agreement with GOODFELLOW for the injectable Efparepoetinalfa [1] - A resolution was passed to transfer equity stakes in a subsidiary and waive the right of first refusal [1] - The company also approved changes to the registered address and name of a subsidiary [1]